Influence of a high single subcutan dose of unfractionated heparin on platelet function in dogs;Wirkung einer einmaligen hohen subkutanen dosis unfraktionierten heparins auf die thrombozytenfunktion beim hund

Berliner und Munchener Tierarztliche Wochenschrift

Volumn 113, Issue 2, 2000, Pages 60-64

  Mischke, R ^a   Nimmerfall, K ^b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b NONE

Author keywords

Capillary bleeding time; Dog; Heparin; In vitro bleeding time; Platelet aggregation; Platelet function

Indexed keywords

ADENOSINE DIPHOSPHATE; COLLAGEN; HEPARIN;

ANIMAL; ARTICLE; BLEEDING TIME; DOG; DRUG EFFECT; FEMALE; MALE; PHYSIOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT;

ADENOSINE DIPHOSPHATE; ANIMALS; BLEEDING TIME; BLOOD PLATELETS; COLLAGEN; DOGS; FEMALE; HEPARIN; INJECTIONS, SUBCUTANEOUS; MALE; PLATELET AGGREGATION; PLATELET COUNT;

ANIMALIA; CANIS FAMILIARIS;

EID: 0033997699     PISSN: 00059366     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Bhargava, A. S., C. Schöbel, P. Günzel (1981): Characterization of a new potent heparin. Arzneim.-Forsch./Drug Res. 30, 79-82.
2. Born, G. V. R. (1962): Aggregation of blood platelets by adenosine diphosphate and ist reversal. Nature 194, 927-929.
3. Breddin, K., J. Bauke (1965): Thrombozytenagglutination und Gefäßkrankheiten. Blut 11, 144-164.
4. Burgess, J. K., B. H. Chong (1997): The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls. Eur. J. Haematol. 58, 279-285.
5. Eidt, J. F., P. Allison, S. Noble, J. Ashton, P. Golino, J. McNatt, L. M. Buja, J. T. Willerson (1989): Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J. Clin. Invest. 84, 18-27.
6. Eika, C. (1971): Inhibition of thrombin induced aggregation of human platelets by heparin. Scand. J. Haematol. 8, 216-222.
7. Eldor, A., B. B. Weksler (1979): Heparin and dextran sulfate antagonize PGI2 inhibition of platelet aggregation. Thromb. Res. 16, 617-628.
8. Heiden, D., C. H. Mielke, R. Rodvien (1977): Impairment by heparin of primary haemostasis and platelet [14 C] 5-hydroxytryptamine release. Br. J. Haematol. 36, 427-436.
9. Heinrich, D., T. Görg, M. Schulz (1988): Effects of unfractionated and fractionated heparin on platelet function. Haemostasis 18, Suppl. 3, 48-54.
10. Hemker, H. C., S. Béguin (1992): The mode of action of heparins in vitro and in vivo. Adv. Exp. Med. Biol. 313, 221-230.
11. Hiebert, L. M., L. B. Jaques (1976): The observation of heparin on endothelium after injection. Thromb. Res. 8, 195-204.
12. Holmer, E. (1980): Anticoagulant properties of heparin and heparin fractions. Scand. J. Haematol. 25, Suppl. 36, 25-39.
13. Jergens, A. E., M. A. Turrentine, K. H. Kraus, G. S. Johnson (1987): Buccal mucosa bleeding times of healthy dogs and of dogs in various pathologic states, including thrombocytopenia, uremia and von Willebrand's disease. Am. J. Vet. Res. 48, 1337-1342.
14. Keidel, A., R. Mischke (1998): Untersuchungen zur klinischen Anwendung des Plättchenfunktionsanalysengerätes PFA-100 beim Hund. Berl. Münch. Tierärztl. Wochenschr. 111, 452-456.
15. Kociba, G. J. (1977): Disseminated intravascular coagulation. In: Kirk, R. W. (Hrsg.): Current veterinary therapy VI. Philadelphia: Saunders, S, 448-451.
16. Krupinski, K., M. Basic-Micic, E. Lindhoff, H. K. Breddin (1990): Inhibition of coagulation and platelet adhesion to extracellular matrix by unfractionated heparin and a low molecular weight heparin. Blut 61, 289-294.
17. Kundu, S. K., E. J. Heilmann, R. Sio, C. Garcia, R. M. Davidson, R. A. Ostgaard (1995): Description of an in vitro platelet function analyzer-PFA-100. Sem. Thromb. Haemost. 21, Suppl. 2, 106-112.
18. Leadley, R. J., C. J. Kasiewski, J. S. Bostwick, R. Bentley, C. T. Dunwiddie, M. H. Perrone (1998): Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin. Arterioscler. Thromb. Vasc. Biol. 18, 908-914.
19. Ljungberg, B., H. Johnsson (1988): In vivo effects of a low molecular weight heparin fragment on platelet aggregation and platelet dependent hemostatsis in dogs. Thromb. Haemost. 60, 232-235.
20. MacIntyre, D. E., R. I. Handin, R. Rosenberg, E. W. Salzman (1981): Heparin opposes prostanoid and non-prostanoid platelet inhibitors by direct enhancement of aggregation. Thromb. Res. 22, 167-175.
21. Matthias, F. R., H. Ditter (1984): Prophylaxe und Therapie tiefer Venenthrombosen mit Heparin - speziell in der Chirurgie frischer Venenthrombosen. Folia Angiol. 32, 5-8.
22. Merhi, Y., J. Bernier, Y. Marois, R. Guidoin (1995): Acute thrombogenicity of arterial prostheses exposed to reduced blood flow in dogs: Effects of heparin, aspirin, and prostacyclin. J. Cardiovasc. Pharmacol. 26, 1-5.
23. Mikhailidis, D. P., M. A. Barradas, A. M. Mikhailidis, H. Magnani, P. Dandona (1984): Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function. Br. J. Clin. Pharmacol. 17, 43-48.
24. Nimmerfall, K., R. Mischke (1999): Einfluß von unfraktioniertem und niedermolekularem Heparin auf die Thrombozytenaggregation und die In-vitro-Blutungszeit beim Hund. Dtsch. Tierärztl. Wochenschr. (eingereicht).
25. Nolte, I., C. Niemann, S. K. Bowry, K. Failing, G. Müller-Berghaus (1997): A method for measuring capillary bleeding time in non-anaesthetized dogs: Prolongation of the bleeding time by acetylsalicylic acid. J. Vet. Med. A 44, 625-628.
26. Schwarz, H. P., P. L. Turecek, L. Pichler, A. Mitterer, W. Mundt, F. Dorner, J. Rousse, L. Drouet (1997): Recombinant von Willebrand factor. Thromb. Haemost. 78, 571-576.
27. Sobel, M., B. Adelman (1988): Characterization of platelet binding of heparins and other glycosaminoglycans. Thromb. Res. 50, 815-826.
28. Sobel, M., P. M. McNeill, P. L. Carlson, J. C. Kermode, B. Adelman, R. Conroy, D. Marques (1991): Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J. Clin. Invest. 87, 1787-1793.
29. Sudo, Y., B. R. Lucchesi (1996): Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis: a comparison with heparin. J. Cardiovasc. Pharmacol. 27, 545-555.
30. Walenga, J. M., M. Bakhos, H. L. Messmore, J. Fareed, R. Pifarre (1991): Potential use of recombinat hirudin as a an anticoagulant in a cardiopulmonary bypass model. Ann. Thorac. Surg. 51, 271-277.
31. Westwick, J., M. F. Scully, C. Poll, V. V. Kakkar (1986): Comparison of the effect of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. Thromb. Res. 42, 435-447.